1. PREVIOUS GUIDANCE ON MYOPIA CONTROL

While eye care professionals have put forward views on how to slow myopia progression for centuries, the first evidence-based review to make clinical recommendations appears to have been in 2002, based on the only 10 randomized controlled trials to have been conducted at that time. This report concluded that bifocal spectacle lenses and soft contact lenses are not recommended for slowing the progression of myopia in children, nor is the routine use of atropine eye drops. Since that time, more than 170 peer-reviewed articles on myopia control have been published, making it difficult for clinicians to keep abreast of the latest findings and how they should affect the optimum management of their patients. Few, if any, professional bodies have issued documented guidance on the treatment of myopia (in contrast to the correction of the refractive error). While eye care practitioners from across the globe seem concerned about the increasing levels of myopia in their practices, especially in Asia, and report relatively high levels of activity in controlling myopia, most still prescribe single-vision spectacles and contact lenses to their progressing myopes. Hence, there is a need for evidence-based intervention strategies, informed by animal model and genetic studies, with agreement on how myopia should be defined, validated by well-designed and ethically applied clinical trials. The International Myopia Institute (IMI) reports represent the work of more than 85 multidisciplinary experts in the field, who set out to critically review, synthesize, and summarize the research evidence to date (Table 1), and serve to inform both clinical practice and future research.

2. THE IMI REPORT GENERATION PROCESS

As highlighted in the accompanying editorial, the foundation of the IMI was an outcome of the World Health Organization-associated global scientific meeting on Myopia, held at the Brien Holden Vision Institute in Sydney, Australia, in 2015. As part of the IMI’s mission to address identified key issues related to myopia, they approached a group of experts to produce two white papers in November 2015, one focused on Myopia Definitions and Classification, and the other on Definitions and Classification of Clinical Myopia Management Guidelines. With the growing prevalence of myopia, already at epidemic levels in some countries, there is an urgent need for new management approaches. However, with the increasing number of research publications on the topic of myopia control, there is also a clear necessity for agreement and guidance on key issues, including on how myopia should be defined and how interventions, validated by well-conducted clinical trials, should be appropriately and ethically applied. The International Myopia Institute (IMI) reports the critical review and synthesis of the research evidence to date, from animal models, genetics, clinical studies, and randomized controlled trials, by more than 85 multidisciplinary experts in the field, as the basis for the recommendations contained therein. As background to the need for myopia control, the risk factors for myopia onset and progression are reviewed. The seven generated reports are summarized: (1) Defining and Classifying Myopia, (2) Experimental Models of Emmetropization and Myopia, (3) Myopia Genetics, (4) Interventions for Myopia Onset and Progression, (5) Clinical Myopia Control Trials and Instrumentation, (6) Industry Guidelines and Ethical Considerations for Myopia Control, and (7) Clinical Myopia Management Guidelines.

Keywords: myopia control, myopic progression, clinical guidelines, definition, interventions

IMI – Myopia Control Reports Overview and Introduction

James S. Wolffsohn,1 Daniel Ian Flitcroft,2 Kate L. Gifford,3 Monica Jong,4 Lyndon Jones,5 Caroline C. W. Klaver,6 Nicola S. Logan,1 Kvin Naidoo,7 Serge Resnikoff,4 Padmaja Sankaridurg,4 Earl L. Smith III,8 David Troilo,9 and Christine F. Wildsoet10

1Ophthalmic Research Group, Aston University, Birmingham, United Kingdom
2Children’s University Hospital, University College Dublin and Dublin Institute of Technology, Dublin, Ireland
3Private Practice and Queensland University of Technology, Queensland, Australia
4Brien Holden Vision Institute and School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia
5Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, Canada
6Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands
7African Vision Research Institute, University of KwaZulu-Natal, Durban, South Africa
8College of Optometry, University of Houston, Houston, Texas, United States
9College of Optometry, State University of New York, New York, New York, United States
10Berkeley Myopia Research Group, School of Optometry & Vision Science Program, University of California Berkeley, Berkeley, California, United States

Correspondence: James S. Wolffsohn, Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK; j.s.w.wolffsohn@aston.ac.uk.
Submitted: October 16, 2018
Accepted: October 20, 2018
Citation: Wolffsohn JS, Flitcroft DI, Gifford KL, et al. IMI – Myopia control reports overview and introduction. Invest Ophtalmol Vis Sci. 2019;60:M1–M19. https://doi.org/10.1167/iovs.18-25980

With the growing prevalence of myopia, already at epidemic levels in some countries, there is an urgent need for new management approaches. However, with the increasing number of research publications on the topic of myopia control, there is also a clear necessity for agreement and guidance on key issues, including on how myopia should be defined and how interventions, validated by well-conducted clinical trials, should be appropriately and ethically applied. The International Myopia Institute (IMI) reports represent the work of more than 85 multidisciplinary experts in the field, who set out to critically review, synthesize, and summarize the research evidence to date (Table 1), and serve to inform both clinical practice and future research.
TABLE 1. International Myopia Institute (IMI) Report Subcommittee Members

**IMI – Defining and Classifying Myopia**

- Daniel Ian Flitcroft, MBBS, PhD
  - Children’s University Hospital, University College Dublin and Dublin Institute of Technology, Dublin, Ireland
- Mingguang He, MD, PhD
  - Centre for Eye Research Australia; Ophthalmology, Department of Surgery, University of Melbourne, Melbourne, Australia
- Jost B. Jonas, MD
  - Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg, Mannheim, Germany
- Monica Jong, PhD
  - Brien Holden Vision Institute and School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia
- Kevin Naidoo, OD, PhD
  - African Vision Research Institute, University of KwaZulu-Natal, Durban, South Africa
- Kyoko Ohno-Matsui, MD, PhD
  - Tokyo Medical and Dental University, Tokyo, Japan
- Jugnoo Rahi, MBBS, PhD
  - Institute of Child Health, University College London and Great Ormond Street Hospital for Children, London, United Kingdom
- Serge Resnikoff, MD, PhD
  - Brien Holden Vision Institute and School of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia
- Susan Vitale, PhD, MHS
  - National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States
- Lawrence Yannuzzi, MD
  - The Vitreous, Retina, Macula Consultants of New York; The LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and Throat Hospital, New York, New York, United States

**IMI – Experimental Models of Emmetropization and Myopia**

- David Troilo, PhD
  - SUNY College of Optometry, State University of New York, New York, New York, United States
- Earl L. Smith III, OD, PhD
  - College of Optometry, University of Houston, Houston, Texas, United States
- Debora Nicka, PhD
  - Biomedical Sciences and Disease, New England College of Optometry, Boston, Massachusetts, United States
- Regan Ashby, PhD
  - University of Canberra, Health Research Institute, Canberra, Australia
- Andrei Tkatchenko, MD, PhD
  - Department of Ophthalmology, Columbia University, New York, New York, United States
- Lisa A. Ostrin, OD, PhD
  - College of Optometry, University of Houston, Houston, Texas, United States
- Tim J. Gawne, PhD
  - College of Optometry, University of Alabama Birmingham, Birmingham, Alabama, United States
- Machelle T. Pardue, PhD
  - Biomedical Engineering, Georgia Tech College of Engineering, Atlanta, Georgia, United States
- Jody A. Summers, PhD
  - College of Medicine, University of Oklahoma, Oklahoma City, Oklahoma, United States

**IMI – Myopia Genetics**

- Chea-su Kee, BSc Optom, PhD
  - School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Special Administrative Region, China
- Falk Schroedl, MD
  - Department of Ophthalmology and Anatomy, Paracelsus Medical University, Salzburg, Austria
- Siegfried Wahl, PhD
  - Institute for Ophthalmic Research, University of Tuebingen, Zeiss Vision Science Laboratory, Tuebingen, Germany
- Lyndon Jones, PhD, DSc, FCOptom
  - Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, Canada

**IMI – Interventions for Myopia Onset and Progression**

- Milly S. Tedja, MD
  - Department of Ophthalmology, Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
- Annechien E. G. Haarman, MD
  - Department of Ophthalmology, Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
- Jaakko Kaprio, MD, PhD
  - Faculty of Sport and Health Sciences, University of Jyväskylä, Jyväskylä, Finland
- David A. Mackey, MD, PhD
  - Department of Ophthalmology, Menzies Institute of Medical Research, University of Tasmania, Hobart, Tasmania, Australia
- Jeremy Guggenheim, MCOptom, PhD
  - School of Optometry & Vision Sciences, Cardiff University, Cardiff, United Kingdom
- Christopher J. Hammond, MD, PhD
  - Section of Academic Ophthalmology, School of Life Course Sciences, King’s College London, London, United Kingdom
- Virginie J. M. Verhoeven, MD, PhD
  - Department of Ophthalmology, Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
- Caroline C. W. Klaver, MD, PhD
  - Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands

**IMI – Myopia Control Reports Overview and Introduction**

- Scott Read, BAppSci Optom (Hons), PhD
  - School of Optometry & Vision Science, Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia
TABLE 1. Continued

IMI – Myopia Control Reports Overview and Introduction

Padmaja Sankaridurg, BOptom, PhD
Brien Holden Vision Institute, School of Optometry and Vision Science, University of New South Wales, Sydney, Australia
Seang-Mei Saw, MPH, PhD
Saw Swee Hock School of Public Health, National University of Singapore, Singapore
Klaus Trier, MD
Trier Research Laboratories, Hellerup, Denmark
Jeff J. Walline, OD, PhD
The Ohio State University College of Optometry, Columbus, Ohio, United States
Pei-Chang Wu, MD, PhD
Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
James S. Wolfsohn, FCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United Kingdom

IMI – Clinical Myopia Control Trials and Instrumentation

James S. Wolfsohn, FCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United Kingdom
Pete S. Kollbaum, OD, PhD
Indiana University, School of Optometry, Bloomington, Indiana, United States
David A. Berntsen, OD, PhD
The Ocular Surface Institute, College of Optometry, University of Houston, Houston, Texas, United States
David A. Atchison, DSc
School of Optometry & Vision Science, Institute of Health & Biomedical Innovation, Queensland University of Technology, Australia
Alexandra Benavente, MCOptom, PhD
SUNY College of Optometry, New York, New York, United States
Arthur Bradley, PhD
Indiana University, School of Optometry, Bloomington, Indiana, United States
Hetal Buckhurst, MCOptom, PhD
School of Health Professions, Peninsula Allied Health Centre, Plymouth University, Plymouth, United Kingdom
Michael Collins, Dip App Sc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland, Australia
Takashi Fujikado, MD, PhD
Department of Applied Visual Science, Osaka University Graduate School of Medicine, Osaka, Japan
Takahiro Hiraoka, MD, PhD
Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
Masakazu Hirota, MSc
Department of Applied Visual Science, Osaka University Graduate School of Medicine, Osaka, Japan
Debbie Jones, FCOptom
School of Optometry & Vision Science, University of Waterloo, Waterloo, Ontario, Canada
Nicola S. Logan, MCOptom, PhD
Ophthalmic Research Group, Aston University, Birmingham, United Kingdom
Linda Lundström, PhD
Applied Physics, KTH Royal Institute of Technology, Stockholm, Sweden
Scott A. Read, BAppSci Optom, PhD
School of Optometry & Vision Science, Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia

TABLE 1. Continued

IMI – Industry Guidelines and Ethical Considerations for Myopia Control

Hidemasa Torii, MD, PhD
Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
Kovin Naidoo, OD, PhD
African Vision Research Institute, University of KwaZulu-Natal, Durban, South Africa

IMI – Clinical Myopia Management Guidelines

Lyndon Jones, PhD, DSc, FCOptom
Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Waterloo, Canada
Bjorn Drobe, MSc, PhD
Essilor R&D, Vision Sciences AMERA, Center of Innovation and Technology AMERA, Singapore, Singapore
José Manuel González-Méijome, OD, PhD
Clinical & Experimental Optometry Research Lab, Center of Physics (Optometry), School of Science, University of Minho, Braga, Portugal
Lyle Gray, PhD, BSc, Dip Optom
Department of Vision Sciences, Glasgow Caledonian University, Glasgow, United Kingdom
Timo Kratzer, Dipl Phys
Carl Zeiss Vision International GmbH, Aalen, Germany
Steve Newman
Menicon Company Limited, Nagoya, Japan
Jason J. Nichols, OD, MPH, PhD
University of Alabama at Birmingham, School of Optometry, Birmingham, Alabama, United States
Arne Ohlendorf, PhD
Carl Zeiss Vision International GmbH, Aalen, Germany
Stephanie Ramdass, OD, MS
Vision Research Institute, Michigan College of Optometry, Ferris State University, Big Rapids, Michigan, United States
Jacineto Santodomingo-Rubido, MSc, PhD
Menicon Company Limited, Nagoya, Japan
Katrina L. Schmid, PhD
School of Optometry and Vision Science, Institute of Health and Biomedical Innovation, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia
Donald Tan, FRCS
Ophthalmology and Visual Sciences Academic Clinical Program, Duke-National University of Singapore Medical School, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
Kah-Ooi Tan, MBA, PhD
Brien Holden Vision Institute, Sydney, New South Wales, Australia
Fuensanta A. Vera-Díaz, OD, PhD
New England College of Optometry, Boston, Massachusetts, United States
Yee-Ling Wong, BSc
Essilor R&D, Vision Sciences AMERA, Center of Innovation and Technology AMERA, Singapore, Singapore
Kate L. Gifford, BAppSc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland, Australia
Serge Resnikoff, MD, PhD
Brien Holden Vision Institute, Sydney, New South Wales, Australia

IMI – Myopia Management Guidelines

Kate L. Gifford, BAppSc (Optom), PhD
Queensland University of Technology, Brisbane, Queensland, Australia
Kathryn Richdale, OD, PhD
University of Houston, Houston, Texas, United States
Myopia (high myopia, pathologic myopia, and myopic macular degeneration). An IMI steering and an advisory board were established also in November 2015 at the American Academy of Ophthalmology meeting in Las Vegas to oversee the process. A separate initiative at a similar time, led by James Wolffsohn and Nicola Logan of Aston University (Birmingham, United Kingdom), approached leading experts in the field to establish a steering committee to put together an evidence-based global consensus on myopia control, in particular to inform clinicians, based on the well-established approach taken by the Tear Film and Ocular Surface Society. The two groups agreed to bring the initiatives together at a meeting at The Association for Research in Vision and Ophthalmology (ARVO) in May 2016 in Seattle. It was agreed that Earl Smith and James Wolffsohn would chair the initiative supported by the IMI. Monica Jongs from the Brien Holden Vision Institute facilitated the entire process. In March 2017, the new white papers to accompany the original two had been agreed on and potential chairs approached.

In developing this set of reports, the IMI has collaborated closely with the past and present organizers of The International Myopia Conference (IMC), an international event that has been in existence since 1964 and is now a biennial event (Table 2). The IMC is devoted to promoting all aspects of myopia research at the basic level through to translational research and clinical myopia research, thereby bringing together a wide range of disciplines. The attendance at the congress reflects the diversity of persons involved in myopia-related activities, including researchers, academics, practitioners, policy makers, industry representatives, and students. The IMC started more than 50 years ago; however, it was Sek Jin Chew in collaboration with Josh Wallman who was instrumental in reviving the conference in 1990. The site-hosting organization and organizing committee change for each meeting, thus ensuring diversity at many levels. Chew and Wallman re-established the IMC meetings, using local organizing committees beginning in 1990, adopting the numbering of committees owing to their valuable experience, but the review process outlined ensured no undue influence. The sponsors contributed to publication costs of the International Myopia Conference reports. The appointed harmonizer to each report (see Table 3) presented to a special session at the IMC in Birmingham, United Kingdom, in September 2017 and the report committee membership was expanded based on further interest and feedback. The report committees also met to finalize their paper’s outline and to allocate the workload based on the original Myopia International Research Foundation sponsored meetings.

Experts in the field (as identified by the IMI and IMC) were approached for expressions of interest to contribute to one of the reports of their choice. An inclusive approach was adopted, while limiting the number of participants from any one research group to ensure a balanced representation. Discussion between the chairs resulted in report selection for each individual, based on their expertise. The then IMI steering board (David Friedman, Mingguang He, Jonas Jost, Ohn Matsui Kyoko, Kovin Naidoo [chair], Jason Nichols, Serge Resnikoff, Earl Smith, Hugh Taylor, Christine Wildsoet, James Wolffsohn, Tien Wong) and the chairs met at ARVO in May 2018 the IMI steering committee received reports from each of the committee chairs. Reviewer comments were received by the report chairs and addressed one by one, as occurs in a traditional peer review of academic manuscripts, to ensure all views were considered. Experts in the field who work for industry were not excluded from the report committees owing to their valuable experience, but the review process outlined ensured no undue influence. The chairs (Table 3) presented to a special session at the IMC in Birmingham, United Kingdom, in September 2017 and the report committee membership was expanded based on further interest and feedback. The report committees also met to finalize their paper’s outline and to allocate the workload immediately after the meeting. Shortly after this meeting an agreement was put in place to publish all the reports in a special issue of Investigative Ophthalmology & Visual Science (IOVS). By early 2018, the draft report was put together from the contributions of each committee, and authorship was determined on the basis of contribution. The draft reports were circulated to that committee to review as a whole, to ensure all issues were adequately addressed. In March 2018, the report drafts were circulated to all 88 members of the IMI committees (who came from 17 counties) for review by July. At ARVO in May 2018 the IMI steering committee received reports from each of the committee chairs. Reviewer comments were received by the report chairs and addressed one by one, as occurs in a traditional peer review of academic manuscripts, to ensure all views were considered. Experts in the field who work for industry were not excluded from the report committees owing to their valuable experience, but the review process outlined ensured no undue influence. The sponsors contributed to publication costs of the International Myopia Conference reports. The appointed harmonizer to each report (see Table 3) was then responsible for ensuring the reviewers’ comments had been adequately addressed, that overlap between the

### Table 1. Continued

<table>
<thead>
<tr>
<th>Author</th>
<th>Affiliation</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pauline Kang, BOptom, PhD</td>
<td>University of New South Wales, Sydney, New South Wales, Australia</td>
<td></td>
</tr>
<tr>
<td>Thomas A. Aller, OD</td>
<td>University of California, Berkeley, California, United States</td>
<td></td>
</tr>
<tr>
<td>Carly S. Lam, BSc, PhD</td>
<td>The Hong Kong Polytechnic University, Hong Kong</td>
<td></td>
</tr>
<tr>
<td>Y. Maria Liu, OD, PhD</td>
<td>University of California, Berkeley, California, United States</td>
<td></td>
</tr>
<tr>
<td>Langis Michaud, OD, MSc</td>
<td>University of Montreal, Montreal, Quebec, Canada</td>
<td></td>
</tr>
<tr>
<td>Jeroen Mulder, BOptom, MSc</td>
<td>University of Applied Sciences Utrecht, Utrecht, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Janis B. Orr, BSc, PhD</td>
<td>Aston University, Birmingham, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Kathryn A. Rose, PhD</td>
<td>University of Technology Sydney, New South Wales, Australia</td>
<td></td>
</tr>
<tr>
<td>Kathryn J. Saunders, FCiOptom, PhD</td>
<td>Ulster University, Londonderry, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Dirk Seidel, PhD</td>
<td>Glasgow Caledonian University, Glasgow, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>J. Willem Tideman, MD, PhD</td>
<td>Erasmus Medical Centre, Rotterdam, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Padmaja Sankaridurg, BOptom, PhD</td>
<td>Brien Holden Vision Institute, School of Optometry and Vision Science, University of New South Wales, Sydney, Australia</td>
<td></td>
</tr>
</tbody>
</table>

CREAM, the international Consortium for Refractive Error and Myopia.
reports was minimized (with appropriate cross-referencing), and that the report styles were unified as much as possible.

The harmonizers had a meeting in August 2018 and subsequent email communication to resolve any issues arising. It was acknowledged that some areas of overlap would remain where aspects were approached from a different angle (such as drafting a clinical trial protocol as compared to clinical guidance). The imperative of promoting myopia control as an ethical imperative, due to the evidence-based risk of complications from higher levels of myopia and the availability of treatments with proven effectiveness (compared to the risk of complications from the treatment modality), was of particular note. Hence, the reports promote open communication with patients and their parents/guardians regarding the risk versus benefits, such that a fully informed, joint decision on treatment adoption can be made. Finalized harmonized reports were submitted for publication in IOVS in October 2018.

Table 3. Report Committees, Chairs, and Harmonizers

<table>
<thead>
<tr>
<th>Report Subcommittee</th>
<th>Chair(s)</th>
<th>Harmonizer(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defining and Classifying Myopia</td>
<td>Ian Flitcroft</td>
<td>Earl Smith</td>
</tr>
<tr>
<td>Experimental Models of Emmetropization and Myopia</td>
<td>David Trollo &amp; Earl Smith</td>
<td>Lyndon Jones</td>
</tr>
<tr>
<td>Myopia Genetics</td>
<td>Caroline Klaver</td>
<td>Earl Smith</td>
</tr>
<tr>
<td>Interventions for Myopia Onset and Progression</td>
<td>Christine Wildsoet</td>
<td>James Wolfsohn</td>
</tr>
<tr>
<td>Clinical Myopia Control Trials and Instrumentation</td>
<td>James Wolfsohn</td>
<td>Kevin Naiddoo</td>
</tr>
<tr>
<td>Industry Guidelines and Ethical Considerations for Myopia Control</td>
<td>Lyndon Jones</td>
<td>Serge Resnikoff &amp; Kate Gifford</td>
</tr>
<tr>
<td>Clinical Myopia Management Guidelines</td>
<td>Kate Gifford</td>
<td>Padmaja Sankaridurg</td>
</tr>
</tbody>
</table>

3. Background to the Need for Myopia Control

3.1 Refractive Development

From birth, eye growth continues and refractive state normally undergoes a gradual shift toward emmetropia. In the first 6 months of life, human newborns typically have a variable, but low hyperopic, cycloplegic refractive error with mean of approximately +2.00 diopters (D) (±SD 2.75 D), which shows a normal distribution in the population.\(^3\)\(^4\)\(^6\) Emmetropization over the subsequent 6 to 12 months of age leads to a reduction in hyperopia, and the normal distribution of refractive errors seen in neonates becomes more leptokurtic as the eye matures.\(^7\) For the next several years, hyperopic refractive error will reduce slowly such that, by 5 to 7 years of age, most children will have a refractive error in the low hyperopic range (plano to +2.00 D).\(^3\)\(^6\)\(^8\)\(^9\) In populations with relatively low to modest education levels, refractive error is likely to endure at this level throughout the teenage and adult years.\(^10\) In some individuals, for reasons not well understood, the refractive error will become myopic and is likely to progress for a period of time.

3.2 Myopia Onset

In children younger than 6 years the prevalence of myopia is low.\(^1\)\(^11\)\(^19\) Even in East Asia and Singapore, where the prevalence of myopia is considered to be alarmingly high in young adults, most studies\(^12\)\(^14\)\(^15\)\(^17\)\(^20\)\(^22\) show a prevalence rate of myopia in the pre-6-year-old age group to be less than 5%. In certain populations, myopia has been found in more than 5% of children younger than 6 years, although the prevalence rarely exceeds 10%.\(^11\)\(^14\)\(^22\) Recent studies have reported that the incidence of myopia in this age group may be increasing. Fan et al.\(^23\) report that the prevalence of myopia in Hong Kong preschoolers (mean age, 4.6 ± 0.9 years; range, 3–6 years) has increased significantly from 2.3% to 6.5% over 10 years.

The incidence of myopia increases dramatically in at-risk populations from approximately 6 years of age.\(^24\) Previous studies have linked this change with the beginning of primary school education, and a link between the intensity of the education system and myopia onset has been determined.\(^10\)\(^24\)\(^25\) The annual incidence of myopia onset is reasonably constant between the ages of approximately 7 and 15 years in Chinese populations and, by the age of 18 years, some 80% of the urban-based Han population in China is myopic, regardless of geographic locality.\(^17\)\(^26\)\(^28\) Singapore, Hong Kong, Taiwan, South Korea, and Japan show similar patterns, although incidence may be higher in Singapore, Taiwan, and Hong Kong at younger ages.\(^29\)\(^37\) A systematic review and meta-analysis by Rudnicka et al.\(^37\) has reported an increase of 23% in the prevalence of myopia over the last decade among East Asians.

In Western societies and countries other than those mentioned above, the incidence of myopia onset during childhood years, and thus the corresponding prevalence, is much lower.\(^37\) Most of the myopia cases identified in one study in the United Kingdom was considered to be late onset (16 years or older).\(^58\) Figure 1 illustrates the marked difference in prevalence between East Asian and white children from the meta-analysis of Rudnicka et al.\(^37\) Of ethnicities reported in the meta-analysis, populations in south Asian, black populations in Africa, and Hispanics tended to have lower prevalence than Western white populations, with South-East Asians, black populations not in Africa, Middle Eastern/North African populations, Native Hawaiians, and American Indians showing higher prevalence than white populations, but still much lower than East Asians.\(^7\)

![Figure 1](https://example.com/figure1.png)

**Figure 1.** Modeled prevalence of myopia by age for East Asian and white children and teenagers from a systematic review and quantitative meta-analysis fitted to the year 2005. Graph created from data in Table 3 of Rudnicka et al.\(^37\)
Models, such as those reviewed in the accompanying IMI–Defining and Classifying Myopia Report, are likely to be efficient in predicting myopia onset, due in part at least, to identification of a process of myopic shift already under way. Since the predominant refractive error of young children is usually a low degree of hyperopia, and the consensus diagnostic criterion for myopia is \(-0.50\) D, there is clearly a transition stage of refractive development for those destined to become myopic. The onset of the myopic trajectory is relatively sudden compared to a subtle loss of hyperopia seen in those who remain emmetropic. The myopic shift and acceleration of axial elongation that precedes the onset of myopia may be evident up to 4 years earlier and does not seem to vary between different ethnicities. The high predictive value of the models of Zadnik et al. and Zhang et al. is therefore likely based on detection of values of refractive error and ocular biometry during the transition phase, which depart from those found in emmetropes of the same age.

### 3.3 Myopia Progression

Progression of myopic refractive error tends to be studied less frequently than onset and prevalence in population-based studies. However, understanding the mechanisms and risk factors for both onset and progression, and the degree to which they vary, are important, so the phenomena are considered separately here. Longitudinal studies are optimal, but are resource intensive and consequently uncommon. Cross-sectional studies are useful when the mean refractive errors of myopes are segregated by age.

Donovan and colleagues have conducted a meta-analysis of studies reporting myopia progression rates in children of Asian or European descent living in urban areas and corrected with single-vision spectacles. The analysis uses data from 20 studies, 14 intervention trials, and 6 longitudinal observation studies, to predict the progression of myopia and shows that among existing myopes, progression rate declines with increasing age. For example, according to the equation provided in their article, data for Chua et al. were obtained by averaging progression rates for given ages from their Figure 2.

![FIGURE 2. Refractive shift among myopic children by age. Data from Donovan et al. were digitized by using ImageJ (http://imagej.nih.gov/ij/) provided in the public domain by the National Institutes of Health, Bethesda, MD, USA) and replotted, and the best fit line for Asians was taken from the equation provided in their article. Data for Chua et al. were obtained by averaging progression rates for given ages from their Figure 2.](image)

The progression rates presented by Donovan et al. arise principally from control groups of intervention trials, which may not be representative of the general population. For example, parents of participants in such trials may have enrolled them because of concern that their children’s myopia was progressing at a rapid rate when compared with their peers. Population-based and school-based studies tend to report somewhat slower progression. In a rural district in China with baseline data collected in 1998, a total of 4662 myopic children aged 5 to 9 years for an average of 11.2 years. While this was a hospital-based study, and therefore not necessarily representative of the population at large, the progression rate of approximately \(-0.50\) D/y between the ages of 7 and 13 years was surprisingly modest. Hsu and coworkers have reviewed a population-based cohort in Taiwan of 3256 myopic children, of average age 7.5 years, after 1 year and noted average progression in the group of only \(-0.42\) D, well below that predicted by Donovan et al. Some of these children were being treated with cycloplegics to slow myopia progression and all had been exposed to a large-scale eye care education program, which may explain the lower progression rate. Most recently, Wu et al. have found annual progression of \(-0.79\) D among a school-based control population of 89 myopes aged 6 and 7 years in Taiwan. This is also less than predicted by Donovan et al., but it should be noted that those in the sample population receiving myopia treatment were excluded from the analysis.

Further details of likely progression can be obtained from centile progression curves. Chen et al. have constructed reference age-specific centile curves of refraction from cross-sectional population-based data from the Guangzhou Refractive Error Study in Children. However, apparent progression among the myopes between ages of 7 and 12 years is observed to be only approximately \(-0.5\) to \(-0.6\) D/y, comparatively constant across ages, and less again than that of Donovan et al., particularly at a younger age. The implications of these differences are not clear. Tideman et al. have also produced age-specific centile curves for axial length. The relative functionality of these curves compared to those for refractive error is yet to be determined.

Based on the above literature review, greater myopia progression rates are expected at younger ages (i.e., \(-0.50\) to \(-1.00\) D/y for 6 to 9-year-olds) than at older ages (i.e., \(-0.35\) to \(-0.75\) D for those older than 10 years).
3.4 High Myopia

One of the major ethical challenges for practitioners is accurate identification of those at risk of becoming highly myopic or, at the very least, of those whose myopia is progressing at an unacceptably fast rate. Few analyses are available on this topic, but the breakdown by Chua et al.\(^48\) probably represents the most comprehensive data available. They have found age of onset of myopia to be the strongest predictor of high myopia among Singaporean children.\(^48\) As expected, duration of onset of myopia to be the strongest predictor of high myopia. For children with high myopia at age 11 years, there was an 87% chance that the child became myopic at 7 years of age or younger or had a duration of myopia progression of 4 years or more. Reports from other countries (Denmark, Argentina, United Kingdom) reliably reproduce this observation.\(^55–57\) However, in contrast to the report by Chua and colleagues,\(^48\) Williams et al.\(^57\) have found that age of onset only accounts for a modest proportion (approximately 15%) of the variance in severity of myopia.

3.5 Adult-Onset Myopia and Progression

Most of the myopia cases in one study in Britain were considered to be late onset (16 years or older).\(^58\) Although myopia onset past the adolescent stage of life is of clinical interest and has shown an association with environmental factors,\(^59\) eye care practitioners are generally more concerned from an ethical standpoint with identifying patients at risk for development of higher degrees of myopia, which typically involves juvenile-onset myopia and its associated potential to progress to sight-threatening pathology.\(^60\)

The prevailing perception is that myopia stabilizes in the late teenage years.\(^41\) Certainly, annual progression in most myopic patients slows with time and for many myopes whose condition has progressed through the teenage years, myopia will stabilize before they reach 20 years of age. However, there are patients whose myopia will continue to progress through adult years.\(^58–60\) These patients include those doing intense near work, especially students, and those who have higher degrees of myopia. Continued assessment of refraction and initiation of treatment in patients showing continued progression are warranted. Higher levels of myopia will result from continued progression through adulthood, placing these individuals at higher risk for development of myopia-associated pathologies.

3.6 Genetic and Environmental Risk

Risk factors for myopia onset have been identified and included in a number of multivariate models, although to our knowledge there is currently no comprehensive clinical model that provides good predictive value, aside from those using refractive or biometric information. McMinnis\(^84\) has provided a review of risk factors for onset and progression of myopia and produced a comprehensive table of those factors and how they may influence the prognosis and treatment decisions for individual patients. However, he also notes that the lack of clinical data on the topic of risk “undermines the confidence with which individual prognoses and clinical decisions about interventions can be made.”

3.6.1 Myopia Onset.

**Genetics and Personal Characteristics.** Heritability statistics can be used to estimate the proportion of variation in a phenotypic trait of a population that is due to genetics, and further details can be found in the accompanying IMI – Myopia Genetics Report.\(^62\) Heritability estimates for myopia vary from 0.11 to 0.98, the latter higher value being found among a highly specific group of Finnish female twins aged 28 to 29 years.\(^63,64\) A meta-analysis\(^65\) places heritability at 0.71 for refractive error, which would suggest that the majority of influence is from genetics rather than environment.

Genome-wide association studies (GWAS)\(^66\) have demonstrated complex inheritance of refractive error traits, with identification of more than 150 gene loci associated with myopia and good correlation between studies. However, the identified loci explain a meagre percentage of the variance in refractive error.\(^67\) For example, a genetic risk score (GRS) has estimated that these loci explain only 0.6% and 2.3% of the variance in refractive error at ages 7 and 15 years, respectively.\(^68\) The difference between heritability from twin studies and GWAS is known as “missing heritability” or the “heritability gap” and is a well-known characteristic of other phenotypes and diseases.\(^66\)

While the nature versus nurture debate continues in relation to myopia development, recognition of the importance of gene-environment interactions in phenotypic expression has been a significant step forward. Fan et al.\(^69\) have tested for evidence of interactions between near work or time spent outdoors and 39 previously identified loci from GWAS in refractive development in a pediatric cohort. Five variants have shown apparent interaction with near work, while neither variant nor GRS effects were altered with time outdoors.\(^68\)

The most useful clinical indicator for genetic risk short of genetic testing is parental history of myopia. Older studies demonstrating this association have been reviewed by Goss and Jackson.\(^69\) Studies since that time show significant association between number of myopic parents and incident myopia, as summarized in a recent meta-analysis.\(^70\) Odds ratios (ORs) ranging from 1.44 to 2.96 for having a myopic child compared to not having a myopic child were calculated, depending on the number of myopic parents and adjustment for bias and missing studies.\(^71\) More recent studies confirm the connection.\(^27,71–76\) Parental myopia has also been found to interact with other risk factors. In one study of 1770 grade-7 Chinese students, those with close reading distances and two myopic parents have a 26-fold higher odds for prevalent myopia than children with reading distances of greater than 20 cm and no myopic parents.\(^77–79\) Also, unsurprisingly, parental myopia correlates with certain ocular components, particularly axial length.\(^79,80\)

There are some further considerations around parental myopia as a risk factor. The additive genetic portion of phenotypic variance is smaller in younger families, reflecting the trend for increasing environmental influences.\(^81\) The odds of a child with two myopic parents becoming myopic is thus different to the odds of a myopic child having two myopic parents. In part, this stems from increased myopia prevalence, meaning that there will likely be more children with myopia than there are parents with myopia.\(^82\) Number of myopic parents is a relatively gross instrument and a knowledge of degree of myopia in family members may be a more useful factor for predicting progression.\(^61,82\) Because of these factors, the sensitivity of number of myopic parents in predicting childhood myopia is correspondingly low.\(^83,88\)

Rudnicka et al.\(^77\) also have found that sex differences emerge in myopia prevalence at approximately 9 years of age in whites and East Asians. By 18 years of age, white females have 2.0 (95% confidence interval [CI], 1.4–2.9) times the odds of myopia as white males, and East Asian females have 2.3 (95% CI, 2.0–2.6) times the odds of myopia as East Asian males. Others\(^27,71,75\) since have confirmed the propensity for greater myopia prevalence among females. The extent to which this influence is environmental as opposed to genetic has yet to be determined.
Rose et al.94 have found that the prevalence of myopia in 6- to 7-year-old children of Chinese ethnicity is significantly lower in Sydney, Australia (3.3%) than Singapore (29.1%). In their large meta-analysis of childhood myopia prevalence from population-based surveys, Rudnicka et al.57 have shown striking differences in prevalence among school-aged children of Eastern Chinese ancestry, based on their country of residence (Fig. 3). Among South Asian children living in Australia, England, or Singapore, myopia was five times as likely compared to those living in India or Nepal. There was no apparent difference in prevalence of myopia among white children in studies from Europe, United States, and Oceania.

The authors also determined that children from urban environments have 2.6 (95% CI, 1.8–3.9) times higher odds of myopia than those from rural environments.37 Consistent with this finding, population density, home size, and housing type are also significantly associated with refractive error and axial length.95,96 The mediating factors for all of the environmental effects are likely to be a combination of education, near work, and time spent outdoors.

**FIGURE 3.** Modeled prevalence of myopia by age for East Asians by selected country of residence from a systematic review and quantitative meta-analysis adjusted to the year 2005 (except for Mongolia, which is 2003). Graph created from data in Table 4 of Rudnicka et al.57

Physical attributes (height, weight, and body mass index), prenatal history, birth season, intelligence, and socioeconomic status have all been linked to the likelihood of myopia, with varying strengths of association.

**Binocular Vision.** It has long been postulated that myopia onset and progression may be related to dysfunctional accommodation and convergence. An elevated accommodation-convergence/accommodation (AC/A) ratio has been observed before the onset of myopia.4,10,11 This ratio remains higher among myopes than nonmyopes.109,110 It was thought that the presence of lag before onset may produce hyperopic retinal defocus, stimulating myopia onset. However, this effect only appears at the time of onset, not before, and does not seem to impact progression.108,111 An aspect of accommodative lag worthy of mention is that spurious measurement of accommodative error is well documented.112–114 So-called lag may be substantially a function of the measurement technique, where depth of focus and increasing negative spherical aberration with accommodation and developing myopia are not taken into account.

The shift in refraction (in terms of a reduction in hyperopia) observed in those who will become myopic compared to those who remain emmetropic begins several years before diagnosis. Changes to the AC/A ratio merely seem to parallel such changes. Accommodative lag does not seem to appear until several years before diagnosis, not before, and does not seem to impact progression.115,116 Thus, while binocular vision attributes are an interesting research adjacency in the onset and development of myopia, from our current knowledge they do not seem to add any additional benefit in risk assessment over refraction and biometric parameters, genetics, or environmental effects.

**3.6.2 Myopia Progression.** Compared with onset, there is a lower volume of literature describing risk of progression for existing myopes other than age and initial refractive error. Some studies have looked at group progression, including emmetropes and hyperopes as well as myopes in their analyses, which does not allow specific interpretation regarding progression among myopes.
**4.50 and**

Different environments does not seem to have been undertak-

...in progression rates between ethnically similar populations in

Western societies; however, a thorough review of differences

among Asian children living in Asia compared to those living in

Environment is also likely to play a role in myopic progression

...did not find an effect of ethnicity on progression rates.

Environment is also likely to play a role in myopic progression

rates, which may be inferred from higher degrees of myopia

among Asian children living in Asia compared to those living in

Western societies; however, a thorough review of differences

in progression rates between ethnically similar populations in

different environments does not seem to have been undertak-

In their study, Gwiazda et al. \[117\] found that the number of

myopic parents is a risk factor for high myopia. Some studies

support the proposition that parental myopia is associated

with faster progression rates, where others do not.\[91,118,119\]

Females show faster progression than males according to

Donovan et al. \[96\] (\(−0.80\) D/y and \(−0.71\) D/y, respectively, at

mean age 8.8 years) and Zhou et al. \[98\] (OR, 1.45; 95% CI, 1.12-

1.84). However, such a difference is not evident in the study of

Gwiazda et al. \[117\].

**Environment.** In their meta-analysis, Xiong et al. \[87\] report

that outdoor time is not effective in slowing progression in eyes

that are already myopic. However, a more recent prospective

study\[52\] suggests that outdoor time does have a protective effect

on rate of progression. Subsequent cohort studies\[51,74,118,120\]
yield mixed results. Support for the protective effect of time

spent outdoors on myopia progression may be inferred from

numerous studies that have found a seasonal variation in myopia

progression;\[121-123\] see the accompanying Interventions for

Controlling Myopia Onset and Progression Report.\[88\]

Many of the same environmental factors that are linked to the

incidence or prevalence of myopia are also related to progression.

Multiple articles link near work, with various
descriptors of activity, to myopia progression.\[51,52,74,91,119,120\]

Other associations include urbanization and increasing family

income.\[90,94\]

**Binocular Vision.** Two studies that have considered

binocular vision effects as part of the treatment protocol

(esophoria or low lag of accommodation) have had good

success, suggesting that some aspect of binocular function may

be a risk factor for progression.\[124,125\]

**3.7 Summary of Findings on Risk Factors**

The observations reported above present an unambiguous

message. The younger the age of onset of myopia, the greater

the likelihood that a child will experience progression to

vision-threatening levels of myopia. Practitioners and parents

should be active in addressing both myopia onset and

progression at as young an age as possible. No formal

procedures have been identified that recognize those at risk

of myopia onset before the triggering of the steady progression

in refractive error that ultimately leads to myopia diagnosis.

However, it is clear, for example, that Chinese children living in

urban regions of Asia, who are immersed in an intensive

education environment and have two myopic parents, have a

much greater risk for onset and development of significant

myopia than a Caucasian living in a rural environment in

Australia with no myopic parents. Not all children who are

young at myopia onset will experience progression to high

myopia, but age of onset is the current best determinant for

identifying children at risk of progression. While noting the

risk of high myopia is greatest in those with early onset,

practitioners should also be cognizant that the condition of

some individuals with later onset (say 11 years or older) may

also progress to higher degrees of myopia, where the rate of

progression is high. Practitioners should be vigilant in

identifying and treating those at risk of rapid progression,

regardless of age of onset.

**4. SUBCOMMITTEES AND THEIR REPORT FOCUS AND ADVANCEMENTS**

**4.1 IMI – Defining and Classifying Myopia Report\[39\]**

Myopia has been the topic of scientific study for more than 400

years, but it is only more recently that it has been recognized as

a serious public health issue, owing to its being a significant

cause of visual loss and a risk factor for a range of pathologic

ocular conditions. Its prevalence is increasing on a global basis

and has reached epidemic levels in much of Asia. Myopia has

been defined in a wide variety of ways in the past, such as

based on its assumed etiology, age of onset, progression rate,

degree of myopia (in diopters), and structural complications.

This has led to a confusing accumulation of terms. Hence this

subcommittee’s aim was to provide a standardized set of

terminology, definitions, and thresholds of myopia and its main

ocular complications. A critical review of current terminology

and choice of myopia thresholds was undertaken to ensure

that the proposed standards are appropriate for clinical

research purposes, relevant to the underlying biology of

myopia, acceptable to researchers in the field, and useful for

developing health policy. It is recommended that the many

descriptive terms of myopia be consolidated into the following
descriptive categories:

Myopia: A refractive error in which rays of light entering the

eye parallel to the optic axis are brought to a focus in front of

the retina when ocular accommodation is relaxed. This

usually results from the eyeball being too long from front to

back, but can be caused by an overly curved cornea, a lens

with increased optical power, or both. It is also called

nearsightedness.

With qualifying terms:

Axial Myopia: A myopic refractive state that can be

attributed to excessive axial elongation.

Refractive Myopia: A myopic refractive state that can be

attributed to changes in the structure or location of the

image-forming structures of the eye (i.e., the cornea and

lens).

Secondary Myopia: A myopic refractive state for which a

single, specific cause (e.g., drug, corneal disease, or

systemic clinical syndrome) can be identified that is not a

recognized population risk factor for myopia development.

It was also recommended that in quantitative contexts,

myopia should always be treated as a negative value and that

mathematical comparison symbols be used in their strict

mathematical sense.

To provide a framework for research into myopia preven-
tion, the condition of “premyopia” is defined.
Premyopia: A refractive state of an eye of $\leq +0.75$ D and $>-0.50$ D in children where a combination of baseline refraction, age, and other quantifiable risk factors provides a sufficient likelihood of the future development of myopia to merit preventative interventions.

As a quantitative trait it is recommended that myopia be divided into myopia (i.e., all myopia), low myopia, and high myopia as based on the current consensus of publications:

Myopia: A condition in which the spherical equivalent refractive error of an eye is $\leq -0.5$ D when ocular accommodation is relaxed.

Low Myopia: A condition in which the spherical equivalent refractive error of an eye is $\leq -0.5$ D and $>-6.00$ D when ocular accommodation is relaxed.

High Myopia: A condition in which the spherical equivalent refractive error of an eye is $\leq -6.00$ D when ocular accommodation is relaxed.

Although even low levels of myopia are associated with an increased risk of developing pathologic conditions such as myopia maculopathy and having a retinal detachment, “pathologic myopia” is proposed as the categorical term for the adverse, structural complications of myopia.

Pathological Myopia: Excessive axial elongation associated with myopia that leads to structural changes in the posterior segment of the eye (including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy) and that can lead to loss of best-corrected visual acuity.

A clinical classification is also proposed to encompass the scope of such structural complications.

### 4.2 IMI – Experimental Models of Emmetropization and Myopia Report

Much of our current understanding of characteristics and mechanisms of postnatal eye growth and the development of myopia has come from detailed experimental studies using animal models. These models use a wide range of species, from primates to invertebrates, and include macaque and marmoset monkeys, tree shrews, guinea pigs, mice, chickens, fish, and squids. Considering that these phylogenetically wide-ranging species all possess visually guided eye growth despite differences in ecology, ocular anatomy, visual function, and visual acuity, this supports the hypothesis that visually guided eye growth is an evolutionarily conserved process found in camera-type eyes. Each species provides unique experimental advantages to study the mechanisms of visually guided eye growth and the key signalling pathways that regulate refractive eye development across species; however, anatomic and physiological differences must be taken into account when interpreting and translating results to humans.

The report summarizes the anatomic similarities and differences between the eyes of the principal experimental species used for studies of emmetropization and myopia. Surveying more than 800 published reports on the changes in eye growth and refractive state in response to experimental manipulations of visual conditions, the report offers a summary of the evidence supporting the role of vision in eye development and the mechanisms that underlie the visual regulation of eye growth and emmetropization development. Also discussed are the key operating characteristics of experimental emmetropization to experimentally imposed retinal defocus including local retinal mechanisms controlling regional eye growth, the spatial and temporal integration of visual signals, the impact of simultaneous competing defocus signals, the relationships of various ocular circadian rhythms to induced changes in eye growth, and the critical periods for visual experience-invoked myopia. Studies of the characteristics of the visual signals affecting eye growth are also reviewed and discussed, including the intensity of ambient illumination, the spectral composition of light, longitudinal chromatic aberration, higher-order monochromatic aberrations, and astigmatism. The report reviews the biochemistry of refractive error development, including the roles of various retinal neurotransmitters, neuromodulators, and growth promoters such as dopamine, vasoactive intestinal peptide, melanopsin, glucagon, and insulin, and nitric oxide. Pharmacologic studies of the mechanisms of emmetropization and myopia are discussed including the effects of cholinergic, GABAergic, and adenosine antagonistic drugs and drugs affecting nitric oxide and neuropeptides. Finally, the article reviews the molecular biology of gene expression in the eye and retina and possible gene-environment interactions.

The report reviews and summarizes several confirmed findings from animal models that have provided important proofs of concept that helped to transform treatment strategies for myopia control. These findings include the eye’s ability to detect the sign of retinal defocus and undergo compensatory growth, the local retinal control of eye growth, regulatory changes in choroidal thickness, and the identification of biochemical signal cascades regulating postnatal eye growth and refractive state. Experimental animal models continue to provide new insights into the cellular and molecular mechanisms of eye growth control, including the identification of potential new targets for drug development and future treatments needed to stem the increasing prevalence of myopia and the vision-threatening conditions associated with this disease.

### 4.3 IMI – Myopia Genetics Report

Like other complex traits, myopia has benefitted enormously from the dramatic improvements in DNA technologies and significant reduction in costs for genotyping during the last decade. The IMI - Myopia Genetics Report summarizes the developments in gene identification for refractive error and myopia, and addresses their implications for molecular pathways. An extensive literature search identified almost 200 genetic loci that have been reported for refractive error, myopia, or axial length, and many overlap between these endophenotypes. Risk variants have mostly been identified outside the protein coding regions, and by themselves carry a low risk. Nevertheless, totalling all genetic risk variants in a polygenic risk score shows that those with a high genetic load are $>40$ times more likely to become myopic, and high myopes and high hyperopes can be separated by their genetic score. The most significant contribution of the current gene dissection is the insights into the molecular machinery underlying eye growth. Functions of the annotated genes include retinal cell physiology, light processing, glutamate receptor signalling, extracellular matrix modulation, anterior segment morphology, but also posttranscriptional regulation indicating control of gene expression at the RNA level. In silico and in vitro experiments have shown that all cell types in the retina, but also RPE, vascular bed, and connective tissue are sites of gene expression. This implies that the retinal signalling cascade responding to a visual trigger and leading to eye growth involves a complex network of molecules from many different cells and tissues. Another lesson learned from the genetic studies is that most genes are not eye specific and have a plethora of effects outside of the eye. A fair number of genes for common myopia are involved in a wide range of syndromes,
including neurodegenerative and connective tissue disorders. How this broad spectrum of gene functions leads to scleral remodelling and an increase of axial length remains intriguing. Addressing this “black box” requires taking myopia molecular genetics to the next level: to explore new high-throughput, wide coverage genotyping assays; determine the protein function and the elements that regulate gene expression; investigate how DNA, proteins, and the environment interact to determine eye size; and create possibilities for storage and reuse of massive genomic data. The forecast of understanding and solving myopia makes these challenges worth taking.

4.4 IMI – Interventions for Controlling Myopia Onset and Progression Report

This report examines the evidence basis for various interventions in current use for controlling myopia progression in children, organized under the categories of optical, pharmacologic, environmental (behavioral), and surgical interventions (aimed at stabilizing highly myopic eyes). There is equivocal evidence concerning whether single-vision spectacles cause faster myopic progression than soft contact lenses, but any difference is likely to be clinically irrelevant. Undercorrection is still adopted as a myopia control strategy by some practitioners, yet some but not all clinical trials indicate this strategy has no clinically significant benefit in slowing myopia. Single-vision spectacle lenses designed to alter peripheral defocus had only a small treatment effect, of less than 14% reduction in myopia progression. The treatment effects on myopia progression of bifocal and progressive addition spectacles tend to be larger, although variable and questioned in terms of clinical significance in some cases (6%–51%). Overall, single-vision contact lenses, whether soft or rigid, seem to have little effect on myopia progression, in contrast to significant treatment effects with contact lenses that impose multifocality. Center-distance multifocal lenses have been used off-label successfully, demonstrating a sample size-weighted average of 38%, slowing both myopia progression and axial elongation, although these two assessment elements did not always correspond tightly. Orthokeratology has also proven to be effective in slowing axial length elongation, by between 30% to 55%.

Pharmacologic myopia control trials have principally used atropine, although other muscarinic antagonists such as M1 selective pirenzepine, ocular hypotensive agents including topical timolol (a nonselective β-adrenergic antagonist), and oral 7-methylxanthine, an adenosine antagonist, have also undergone trial. Although the reduction in myopia progression seems to be higher with 1% atropine (around 60%–80%), more recent atropine studies use much lower doses (e.g., 0.01%), with a reduced effect on refractive error retardation (around 45%) and no apparent effect of axial length compared to historical controls, but with fewer side effects and apparent rebound after discontinuation.

Time outdoors appears to be more effective in preventing incident myopia than slowing progression of existing myopia. However, the evidence for vitamin D levels being related to myopic control is weak. Seasonal trends in myopia progression have also been interpreted as indirect evidence of outdoor effects on myopia progression, based on observed faster myopia progression during the darker winter than the brighter summer months. In one study, every additional hour of outdoor time per week has been found to reduce the risk of developing myopia by 2%. In another study, the time children spend engaged in near work outside of school and time spent outdoor were not found to be related, as might be expected. Deployment of wearable technologies in place of questionnaires as study tools may help to resolve apparent inconsistencies and unresolved questions, including whether the quality of indoor lighting is important.

4.5 IMI – Clinical Myopia Control Trials and Instrumentation Report

Clinical trials on myopia control conducted to date were reviewed to inform a consensus on best practice in the design of clinical trials to assess the effectiveness of treatments and the impact on patients. As myopia control interventions will be applied for multiple years throughout the time during which myopia is progressing, and treatment effects have been shown to often reduce after an initial period, it is important that clinical trials evaluate efficacy over a long period (3 years being the recommendation) to ensure continued efficacy beyond any initial treatment effect. Assessment of rebound should also be considered, with a minimum recommended period of 1 year due to seasonal effects. Typical inclusion criteria are cycloplegic spherical or spherical equivalent myopia of at least −0.75 D; astigmatism ≤ 1.00 D; anisometropia ≤ 1.50 D; ages 6 to 12 years; and 20/20 (0.0 logMAR) minimum visual acuity. Exclusion criteria typically preclude rigid contact lens wear; history of previous myopia control treatment; ocular pathology; binocular vision anomaly; medications that may affect pupil size, accommodation, or have an impact on ocular surface; and systemic disease that may affect vision, vision development, or the treatment modality. Appropriate control group selection depends on the intervention being studied, but often myopia control studies cannot be fully masked. Studies with no control group are unable to demonstrate treatment efficacy; as the rate of myopia progression decreases naturally with age and has seasonal variation, it is not possible to distinguish between naturally declining progression and reduced progression attributable to the treatment, without a simultaneously conducted control group. Randomization should be applied to treatment allocation, and stratification by key factors known to influence myopia progression (such as age and race/ethnicity) should be considered. Ocular health, including a slit lamp examination and baseline/periodic dilated fundus examination, along with standardized adverse event reporting, should also be embedded in the trial protocol. Binocular vision associations in myopia control treatments have also been found, so should be investigated at baseline and periodic intervals during the study. Other safety-related assessments include visual acuity and dysphotopsia. Finally, there is not a specific minimum percentage reduction in myopia progression that has been published for a treatment effect to be considered clinically meaningful; any such percentage reduction threshold could theoretically vary with multiple other factors, including duration of treatment, sample population, and study design considerations. Sample size estimates based on currently available measurement variability data are provided.

Outcome measures were classified as primary, secondary, and exploratory. Primary outcome measures are refractive error (ideally assessed objectively with autorefraction of the eye cyclopeged in optical intervention studies with 1% tropicamide) or axial length (ideally measured with noncontact interferometry) or both. Secondary outcome measures focus on patient-reported outcomes (usually assessed by questionnaire and can include the parent’s/guardian’s experience as well as the patient’s) and treatment compliance (ideally in real time, such as with text messaging responses or wearable sensors connected to data loggers). Exploratory outcome measures are particularly useful in trying to understand the mechanism of action and associated factors. These include peripheral refraction (such as measured with autorefractors or wavefront aberrometers), accommodative changes (including
accommodative lag and dynamics), ocular alignment, pupil size, outdoor activity/lighting levels, anterior and posterior segment structural changes (typically imaged with Scheimpflug imaging, optical coherence tomography, and retinal photography with a particular interest in choroidal thickness changes), and tissue biomechanics (of the sclera and cornea).

4.6 IMI – Industry Guidelines and Ethical Considerations for Myopia Control Report

The aim of this subcommittee was to discuss guidelines and ethical considerations associated with the development and prescription of treatments intended for myopia control. A critical review of published articles and guidance documents was undertaken, with a view to carefully consider the ethical standards associated with the investigation, development, registration, marketing, prescription, and use of myopia control treatments.

From an ethical standpoint, deciding whether to implement a myopia control strategy represents a classical medical risk versus benefit ratio. A principal motivation for slowing myopia progression is to prevent the development of vision-threatening disease in later life. However, conclusive evidence that this is the case is unlikely to be available for decades. Nonetheless, if this assumption is correct, then the benefits could be substantial, given the clear relationship between myopia-related ocular pathology and the degree of myopia. Thus, the risk-benefit analysis must take account of the outcomes arising from nonintervention in deciding if implementation of a myopia control strategy with an individual patient is warranted. Other factors to consider include the known improvements in quality-of-life issues arising from the use of corrective devices; adults with pathologic myopia and associated visual impairment report significant social and emotional impacts and reduced life satisfaction. Additional factors that must be accounted for in the decision to undertake myopia control include the regulatory status of the treatment being considered, availability of the treatment, access to appropriate eye care services, and pricing and convenience of the treatment, which are all potential barriers to accessing the myopia control treatment being considered.

These considerations place a burden of responsibility on the practitioner to be fully cognizant of the risks for the patient of developing different levels of myopia, the implications that progression to higher levels of myopia may have, the likely benefits of treatment, the side effects of treatment and other associated factors, so as to provide appropriate advice and care.

Researchers and clinicians often partner with companies to conduct myopia control studies. However, there is a risk for these partnerships to introduce bias, and practitioners should be aware of the importance of evaluating any real (or perceived) conflict of interest when recommending a management plan for myopia control. The interactions between researchers, practitioners, and manufacturers of myopia control treatments should meet the highest possible standards of integrity and transparency and must be declared in the reporting of the results obtained. Relationships between clinicians and patients should not be compromised by commercial or other interests that could subvert the principle that the interests of patients are of primary concern.

Most myopia control treatments are currently off-label in many countries. Most regulatory bodies do not restrict practitioners from discussing off-label treatment uses with their patients. However, given that patients and their families generally assume that a treatment prescribed by their clinician has been proven safe and effective and is supported by scientific evidence, it is recommended that practitioners ensure that a formal informed consent process is adopted, to ensure that the patient (and parents/guardians in some cases) is aware of the risks, benefits, and alternatives for any myopia control treatment discussed.

Regulatory bodies, manufacturers, academics, practitioners, and patients are all stakeholders and play an important role in ensuring the appropriate prescribing and success of myopia control treatments. Approval of a treatment by a regulatory body relies on the risk-benefit assessment and is informed by science, medicine, policy, and judgment, in accordance with applicable legal and regulatory standards. Manufacturers have a large part to play in the ethical decisions around the practitioner's prescribing of myopia control treatments by ensuring that the discussion of the efficacy of a treatment is appropriately reported and that the treatments are manufactured by using rigorous methods to ensure their quality. Academics have an important role in disseminating scientific information related to myopia control treatments, which is typically undertaken in the form of peer-reviewed journal articles, in addition to abstracts and presentations at major scientific conferences. Practitioners have a responsibility to care for their patients by recommending myopia control treatments using evidence-based practice. With a condition as multifactorial and individual as myopia, this means using published evidence along with clinical judgment to determine the best course of action for the young myopic patient. Finally, patients should be well informed about the nature of the product's marketing authorization status for the intended use and, in case of off-label/unlicensed treatments, that the risks associated with the treatment might be unknown. Such information should be provided in a neutral, balanced, and nonbiased way by the practitioner and be accompanied by easily accessible online and printed information.

Undertaking myopia control treatment in minors creates an ethical challenge for a wide variety of stakeholders. Regulatory bodies, manufacturers, academics, and clinicians all share an ethical responsibility to ensure that the products used for myopia control are safe and efficacious and that patients understand the benefits and potential risks of such products.

4.7 IMI – Clinical Myopia Management Guidelines Report

This report draws on the evidence basis outlined principally in the IMI – Interventions for Controlling Myopia Onset and Progression Report for establishing clinical guidelines to inform the management of the progressing myopic patient. This includes risk factor identification from the assessment of refractive error, binocular visual function, parental refraction, and visual environment (such as educational intensity and time spent outdoors) at around ages 6 to 11 years; discussion of the prospect of developing myopia and the associated risks, along with treatment option efficacy, risks, and additional correction benefits with the parents/guardians and the patient in lay terms; setting realistic expectations; gaining informed consent; agreement of compliance and a follow-up schedule; and off-label considerations. Key baseline examination procedures include a detailed ocular and general health history (including parental refractive error, myopia onset, any previous correction/treatment, and time spent outdoors/doing detailed near work), subjective refraction (objective refraction following cycloplegia when indicated), visual acuity, binocular vision (principally vergence) and accommodation (particularly lag and amplitude) assessment, corneal topography (if considering orthokeratology), slit lamp biomicroscopy of the anterior eye (including signs of dry eye disease), intraocular pressure measurement (if considering pharmaceutical treatment), dilat-
ed fundus examination, and ideally noncontact axial length measurement. Exploratory tests that may be used clinically in future include uncorrected relative peripheral refraction, ocular aberrations, pupil size, subfoveal choroidal thickness, and wearable devices to track visual habits and the environment. Treatment strategies need to be agreed upon in conjunction with the patient and parents/guardians with aspects such as their risks/benefits, the patient’s lifestyle, and ease of compliance taken into account. Myopia “calculators” can be useful to visualize the average potential outcome based on research studies, but it must be noted that projections are based on carefully selected subjects examined for between 2 and 5 years only. Owing to the inherent risks of any treatment (contact lens, pharmaceuticals), treatment is not generally advisable until the myopia is visually significant (−0.50 D to −0.75 D), and baseline refractive error will determine the clinical practice.

Occupational references, resources, and recommendations for and dilated fundus examination conducted annually or on the same tests as at baseline, but with cycloplegic refraction for safety and efficacy of the myopia control treatment, performing IMI – Myopia Control Reports Overview and Introduction

Disclosure: D. Troilo, Alcon (C), Essilor (C), Johnson & Johnson Vision (C, P); E.L. Smith III, Brien Holden Vision Institute (F), SightGlass Vision (C), Tree House Eyes, SightGlass Vision (C), P. D. Troilo, Johnson & John Vision (C), P; C.F. Wildsoet, P

IMI – Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies

Disclosure: D.I. Flitcroft, None; M. He, None; J.B. Jonas, P; M. Jong, None; K. Naidoo, None; K. Ohno-Matsui, Bayer (F), Japanese Society for Promotion of Science (F), Novariss (F), Santen (F); J. Ralh, None; S. Resnikoff, Brien Holden Vision Institute (C), S. Vitale, None; L. Yannuzzi, None

Acknowledgments

The authors thank David Sullivan, the chief executive of the Tear Film and Ocular Surface Society, for sharing his expertise in putting together global consensuses. An individual who contributed significantly to this paper wishes to remain anonymous and to together global consensuses. An individual who contributed significantly to this paper wishes to remain anonymous and to together global consensuses. An individual who contributed significantly to this paper wishes to remain anonymous and to together global consensuses.

Disclosure: None; D.A. Mackey, None; J.A. Guggenheim, None; C.J. Hammond, None; V.J.M. Verhoeven, None; C.W. Klaver, Bayer (C), Novartis (C), Optos (C), Topcon (F), Thea Pharma (C)

IMI – Interventions for Controlling Myopia Onset and Progression Report

Disclosure: C.F. Wildsoet, P; A. Chia, None; P. Cho, None; J.A. Guggenheim, None; J.B. Polling, None; S. Read, Cylite Pty Ltd. (F); P. Sankaridurg, Brien Holden Vision Institute (F), SightGlass Vision (C), Tree House Eyes, SightGlass Vision (C), P. D. Troilo, Johnson & John Vision (C), P; C.F. Wildsoet, P

Disclosure: J.S. Wolfsohn, Alcon (F), Allergan (F), Aston EyeTech (F); J. Atiyia Vision (C, Bausch & Lomb (F), BetterVision Ltd. (F), British Contact Lens Association (C), CooperVision (C), EagleEye Eye (F), European Union (F), Eyebag (F), EMPharma (F), EyeDocs (F), Gelflex (F), Innovative UK (F), Johnson & Johnson Vision Care (C, R), Lenstec (F), Medmont (F), Rayner (F), Santen (C, R), Shire (C), Tearlab (F), Thea (F), Opticem (F), University of Houston (C), Visioncare Research (F, C), P

IMI – Clinical Myopia Control Trials and Instrumentation Report

Disclosure: J.S. Wolfsohn, Alcon (F), Allergan (F), Aston EyeTech (F), Atiyia Vision (C), Bausch & Lomb (F), BetterVision Ltd. (F), British Contact Lens Association (C), CooperVision (F, C), EagleEye Eye (F), European Union (F), Eyebag (F), EMPharma (F), EyeDocs (F), Gelflex (F), Innovative UK (F), Johnson & Johnson Vision Care (C, R), Lenstec (F), Medmont (F), Rayner (F), Santen (C, R), Shire (C), Tearlab (F), Thea (F), Opticem (F), University of Houston (C), Visioncare Research (F, C), P; S.P. Klier, Thealife (I), P.J.J. Walline, Bausch & Lomb (F), SightGlass (C), P.C. Wu, None; J.S. Wolfsohn, Alcon (F), Allergan (F), Aston EyeTech (F), Atiyia Vision (C), Bausch & Lomb (F), BetterVision Ltd. (F), British Contact Lens Association (C), CooperVision (C), EagleEye Eye (F), European Union (F), Eyebag (F), EMPharma (F), EyeDocs (F), Gelflex (F), Innovative UK (F), Johnson & Johnson Vision Care (C, R), Lenstec (F), Medmont (F), Rayner (F), Santen (C, R), Shire (C), Tearlab (F), Thea (F), Opticem (F), University of Houston (C), Visioncare Research (F, C), P; P.S. Kolb, Alcon (F), Allergan (F), CooperVision (C, R, F), Johnson & Johnson Vision Care (F, R), Luminopia (F), P; D.A. Bernstein, Bausch & Lomb (F), Vision-eering Technologies (C); D.A. Atchison, Carl Zeiss Vision (F), Cylite Optics (F), ForbeSpecs (F); P. A. Benavente, None; A. Bradley, CooperVision (F, C), Alcon (F, C), Vistakon (F, C), Allergan (F, C); H. Buckhurst, None; M. Collins, Johnson & Johnson Vision Care (F, C, R), Cylite (F), Johnson & Johnson Vision (F, P); T. Fujikado, Nidek (F), Topcon (F), Menicon (F), HOYA (F); P. T. Hiraoka, Johnson & Johnson Vision Care (F), Seed (F), Alpha Corporation (F), Menicon (R), Santen (R), M. Hirota, None; D. Jones, CooperVision (C), Shire (C), Alcon (C); N.S. Logan, CooperVision (F), Visioncare Research (F); L. Lundstrom, Abbott (F), Alcon (F), P; H. Torii, P; S.A. Read, Cylite Pty Ltd. (F), P; K. Naidoo, None
References


## APPENDIX

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>7-MX</td>
<td>7-Methylxanthine</td>
</tr>
<tr>
<td>AC/A</td>
<td>Accommodative convergence to accommodation</td>
</tr>
<tr>
<td>ACES</td>
<td>Anyang Childhood Eye Study</td>
</tr>
<tr>
<td>Add</td>
<td>Bifocal addition</td>
</tr>
<tr>
<td>ADTN</td>
<td>(-/+/-)2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydrophenanthrene</td>
</tr>
<tr>
<td>AF</td>
<td>Retinal autofluorescence</td>
</tr>
<tr>
<td>AL</td>
<td>Axial length</td>
</tr>
<tr>
<td>ALSAC</td>
<td>Avon Longitudinal Study of Parents and Children</td>
</tr>
<tr>
<td>ANSES</td>
<td>French Agency for Food, Environmental and Occupational Health &amp; Safety</td>
</tr>
<tr>
<td>APPL2</td>
<td>Amyloid-like protein-2</td>
</tr>
<tr>
<td>AREDS</td>
<td>Age-Related Eye Study</td>
</tr>
<tr>
<td>ATOM</td>
<td>Atropine in the treatment of myopia</td>
</tr>
<tr>
<td>atRA</td>
<td>All-trans-retinoic acid</td>
</tr>
<tr>
<td>b</td>
<td>Regression coefficient</td>
</tr>
<tr>
<td>BAK</td>
<td>Benzalkonium chloride</td>
</tr>
<tr>
<td>BF</td>
<td>Bifocal</td>
</tr>
<tr>
<td>BHVI</td>
<td>Brien Holden Vision Institute</td>
</tr>
<tr>
<td>BMES</td>
<td>Blue Mountain Eye Study</td>
</tr>
<tr>
<td>BMP</td>
<td>Bone morphogenetic protein</td>
</tr>
<tr>
<td>BS</td>
<td>British standard</td>
</tr>
<tr>
<td>C</td>
<td>Control group</td>
</tr>
<tr>
<td>CA repeats</td>
<td>Cytosine-adenine repeats</td>
</tr>
<tr>
<td>cAMP</td>
<td>Cyclic adenosine monophosphate</td>
</tr>
<tr>
<td>CCL</td>
<td>Collagen cross-linking</td>
</tr>
<tr>
<td>CE</td>
<td>Conformit European</td>
</tr>
<tr>
<td>cGMP</td>
<td>Cyclic guanosine monophosphate</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CLEERE</td>
<td>Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error</td>
</tr>
<tr>
<td>CNV</td>
<td>Choroidal neovascularization</td>
</tr>
<tr>
<td>COI</td>
<td>Conflict of interest</td>
</tr>
<tr>
<td>COMET</td>
<td>Correction of Myopia Evaluation Trial</td>
</tr>
<tr>
<td>CPD</td>
<td>Continuing professional development</td>
</tr>
<tr>
<td>CREAM</td>
<td>Consortium for Refractive Error and Myopia</td>
</tr>
<tr>
<td>DIAP</td>
<td>Dipyretic</td>
</tr>
<tr>
<td>DA</td>
<td>Dapamine</td>
</tr>
<tr>
<td>DFP</td>
<td>Diisopropylfluorophosphate</td>
</tr>
<tr>
<td>ECM</td>
<td>Extracellular matrix</td>
</tr>
<tr>
<td>ECP</td>
<td>Eye care practitioners</td>
</tr>
<tr>
<td>EN</td>
<td>European standard</td>
</tr>
<tr>
<td>cNOS</td>
<td>Endothelial nitric oxide synthase</td>
</tr>
<tr>
<td>ENSL</td>
<td>Enkephalin-, neurtotensin-, and somatostatin-like immunoreactive amacrine cells</td>
</tr>
<tr>
<td>EOM</td>
<td>Early onset myopia</td>
</tr>
<tr>
<td>Eso</td>
<td>Esophoria</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FA</td>
<td>Fluorescin angiography</td>
</tr>
<tr>
<td>FC</td>
<td>Full correction</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>FDM</td>
<td>Form deprivation myopia</td>
</tr>
<tr>
<td>FGF</td>
<td>Fibroblast growth factor</td>
</tr>
<tr>
<td>FRD</td>
<td>Foveal RD</td>
</tr>
<tr>
<td>FU</td>
<td>Follow-up</td>
</tr>
<tr>
<td>GABA</td>
<td>Gamma-aminobutyric acid</td>
</tr>
<tr>
<td>GAG</td>
<td>Glycosaminoglycan</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GCTA</td>
<td>Genome-wide complex trait analysis</td>
</tr>
<tr>
<td>GEWIS</td>
<td>Genome-environment-wide interaction studies</td>
</tr>
<tr>
<td>GLP</td>
<td>Good laboratory practice</td>
</tr>
<tr>
<td>GLP-1</td>
<td>Glucagon-like peptide-1</td>
</tr>
<tr>
<td>GMP</td>
<td>Good manufacturing practice</td>
</tr>
<tr>
<td>GOAL</td>
<td>Guangzhou Outdoor Activity Longitudinal Study</td>
</tr>
<tr>
<td>GP</td>
<td>Gas permeable rigid contact lens</td>
</tr>
<tr>
<td>GRS</td>
<td>Genetic risk score</td>
</tr>
<tr>
<td>GWAS</td>
<td>Genome Wide Association Studies</td>
</tr>
<tr>
<td>GxE</td>
<td>Gene-environment interaction</td>
</tr>
<tr>
<td>HCIP</td>
<td>Healthcare professional</td>
</tr>
<tr>
<td>HM-PRO</td>
<td>High myopia-partial reduction orthokeratology</td>
</tr>
<tr>
<td>HOA</td>
<td>Higher-order aberrations</td>
</tr>
<tr>
<td>Hrs</td>
<td>Hours</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Disease</td>
</tr>
<tr>
<td>ICG</td>
<td>Indocyanine green angiography</td>
</tr>
<tr>
<td>IOP</td>
<td>Intraocular pressure</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional review board</td>
</tr>
<tr>
<td>ISO</td>
<td>International Organization for Standardization</td>
</tr>
<tr>
<td>KORA</td>
<td>Cooperative Health Research in the Region Augsburg</td>
</tr>
<tr>
<td>LCA</td>
<td>Longitudinal chromatic aberration</td>
</tr>
<tr>
<td>L-DOPA</td>
<td>Levodopa (L-3,4-dihydroxyphenylalanine)</td>
</tr>
<tr>
<td>LED</td>
<td>Light emitting diode</td>
</tr>
<tr>
<td>LHI</td>
<td>Lens induced hyperopia</td>
</tr>
<tr>
<td>LIM</td>
<td>Lens induced myopia</td>
</tr>
<tr>
<td>L-NAM</td>
<td>N omega-nitro-L-arginine methyl ester (NOS inhibitor)</td>
</tr>
<tr>
<td>L-NIO</td>
<td>N5-(1-iminoethyl)-L-ornithine (NOS inhibitor)</td>
</tr>
<tr>
<td>L-NMMA</td>
<td>NG-methyl-L-arginine acetate (NOS inhibitor)</td>
</tr>
<tr>
<td>LogMAR</td>
<td>Logarithm minimum angle of resolution</td>
</tr>
<tr>
<td>LOM</td>
<td>Late onset myopia</td>
</tr>
<tr>
<td>LORIC</td>
<td>Longitudinal orthokeratology research in children</td>
</tr>
<tr>
<td>MC</td>
<td>Myopia control</td>
</tr>
<tr>
<td>META-P</td>
<td>Meta-Analysis for Pathologic Myopia Study Group</td>
</tr>
<tr>
<td>MF</td>
<td>Multifocal</td>
</tr>
<tr>
<td>MFSCL</td>
<td>Multifocal soft contact lens</td>
</tr>
<tr>
<td>MM</td>
<td>Myopic maculopathy</td>
</tr>
<tr>
<td>mm</td>
<td>Millimetres</td>
</tr>
<tr>
<td>MMD</td>
<td>Myopic macular degeneration</td>
</tr>
<tr>
<td>MMP</td>
<td>Matrix metalloprotease</td>
</tr>
<tr>
<td>MR</td>
<td>Mendelian randomization</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance image</td>
</tr>
<tr>
<td>MT</td>
<td>Muscarinic toxin</td>
</tr>
<tr>
<td>MTF</td>
<td>Modulation transfer function</td>
</tr>
<tr>
<td>MX</td>
<td>Methylxanthine</td>
</tr>
<tr>
<td>NA</td>
<td>Not applicable</td>
</tr>
<tr>
<td>nNOS</td>
<td>Neuronal nitric oxide synthase</td>
</tr>
<tr>
<td>NO</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>NOS</td>
<td>Nitric oxide synthase</td>
</tr>
<tr>
<td>NP</td>
<td>Not provided</td>
</tr>
<tr>
<td>N-PLA</td>
<td>N-propyl-L-arginine (NOS inhibitor)</td>
</tr>
<tr>
<td>OCT</td>
<td>Ocular coherence tomography</td>
</tr>
<tr>
<td>OK</td>
<td>Orthokeratology</td>
</tr>
<tr>
<td>OLSM</td>
<td>Orinda Longitudinal Study of Myopia</td>
</tr>
<tr>
<td>OMIM</td>
<td>Online Mendelian Inheritance in Man database</td>
</tr>
<tr>
<td>OR</td>
<td>Odds ratio</td>
</tr>
<tr>
<td>PAL</td>
<td>Progressive addition spectacle lenses</td>
</tr>
<tr>
<td>PA-PAL</td>
<td>Peripheral asphericized, progressive addition spectacle</td>
</tr>
<tr>
<td>PG</td>
<td>Proteoglycan</td>
</tr>
<tr>
<td>PMA</td>
<td>Premarket approval</td>
</tr>
<tr>
<td>PMDA</td>
<td>Pharmaceuticals and Medical Devices Agency</td>
</tr>
<tr>
<td>PPG</td>
<td>Pre-proglucagon</td>
</tr>
<tr>
<td>PR</td>
<td>Partial reduction</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>PRO</td>
<td>Patient reported outcomes</td>
</tr>
<tr>
<td>PSR</td>
<td>Posterior scleral reinforcement</td>
</tr>
<tr>
<td>QOL</td>
<td>Quality of life</td>
</tr>
<tr>
<td>QTL</td>
<td>Quantitative trait locus</td>
</tr>
<tr>
<td>r</td>
<td>Correlation coefficient</td>
</tr>
<tr>
<td>RA</td>
<td>Retinoic acid</td>
</tr>
<tr>
<td>RAAB</td>
<td>Rapid assessment of avoidable blindness</td>
</tr>
<tr>
<td>RALDH2</td>
<td>Retinaldehyde dehydrogenase 2</td>
</tr>
<tr>
<td>RAR</td>
<td>Retinoic acid receptor</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized clinical trial/Randomized controlled trial</td>
</tr>
<tr>
<td>RCUK</td>
<td>Research Council of the United Kingdom</td>
</tr>
<tr>
<td>ROC</td>
<td>Recess outside the classroom</td>
</tr>
<tr>
<td>ROMIO</td>
<td>Retardation of myopia in orthokeratology</td>
</tr>
<tr>
<td>RPE</td>
<td>Retinal pigment epithelium</td>
</tr>
<tr>
<td>SAVES</td>
<td>Sydney Adolescent Vascular and Eye Study</td>
</tr>
<tr>
<td>SCL</td>
<td>Soft contact lenses</td>
</tr>
<tr>
<td>SCN</td>
<td>Suprachiasmatic nucleus</td>
</tr>
<tr>
<td>SCORM</td>
<td>Singapore Cohort Study of Risk Factors for Myopia</td>
</tr>
<tr>
<td>SER</td>
<td>Spherical equivalent refraction</td>
</tr>
<tr>
<td>SMS</td>
<td>Sydney Myopia Study</td>
</tr>
<tr>
<td>SNP</td>
<td>Single nucleotide polymorphism</td>
</tr>
<tr>
<td>Specs</td>
<td>Spectacles</td>
</tr>
<tr>
<td>SSGAC</td>
<td>Social Science Genetic Association Consortium</td>
</tr>
<tr>
<td>SSI</td>
<td>Injection-based scleral strengthening</td>
</tr>
<tr>
<td>STARS</td>
<td>Strabismus, Amblyopia and Refractive Error Study in Young Singaporean Children</td>
</tr>
<tr>
<td>SV</td>
<td>Single vision</td>
</tr>
<tr>
<td>TGF</td>
<td>Transforming growth factor</td>
</tr>
<tr>
<td>TIMP</td>
<td>Tissue inhibitor of metalloprotease</td>
</tr>
<tr>
<td>TO-SEE</td>
<td>Toric orthokeratology slowing eye elongation</td>
</tr>
<tr>
<td>UC</td>
<td>Under-corrected</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>USA</td>
<td>United States</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
<tr>
<td>VEGF</td>
<td>Vascular endothelial growth factor</td>
</tr>
<tr>
<td>VIP</td>
<td>Vasoactive intestinal peptide</td>
</tr>
<tr>
<td>WES</td>
<td>Whole-exome sequencing</td>
</tr>
<tr>
<td>WGS</td>
<td>Whole-genome sequencing</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>Yr</td>
<td>Year/years</td>
</tr>
<tr>
<td>ΔBF</td>
<td>Bifocal with base-in prism</td>
</tr>
</tbody>
</table>